The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides, in radionuclide conjugation chemistry, and in the increased availability of alpha-emitters appropriate for clinical use have recently led to patient trials of alpha-particle-emitter labeled radiopharmaceuticals. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle-emitter therapy and to provide guidance and recommendations for human alpha-particle-emitter dosimetry.
Revised: April 19, 2013 |
Published: February 28, 2010
Citation
Sgouros G., J.C. Roeske, M.S. McDevitt, S. Palm, B.J. Allen, D.R. Fisher, and B.A. Brill, et al. 2010.MIRD Pamphlet No. 22 (Unabridged): Radiobiology and Dosimetry of alpha-Particle Emitters for Targeted Radionuclide Therapy.Journal of Nuclear Medicine 51, no. 2:311-328.PNNL-SA-72156.